Cambridge Major Laboratories Europe, B.V. has successfully completed its first FDA inspection at its Weert facility that included a pre-approval inspection and general quality systems audit, which concluded with no Form 483 being issued. CML-Europe supplies development services and niche commercial API’s to a growing customer base.   “This successful FDA inspection represents a major milestone for the CML-Europe facility,” said Peter van Tilburg, president of CML-Europe. “We place Quality ...